glp 1 approved for nash Recent guidelines Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation? GLP-1s like semaglutide are not

Our systematic review and dose-response network meta-analysis aimed to comprehensively evaluate the gastrointestinal adverse events associated with the use of GLP-1 RAs in non-diabetic patients with overweight or obesity

**Offer ends 12/31/26

The role of matrix metalloproteinases in osteoarthritis and possible matrix metalloproteinases targeted treatments Pathogenesis of osteoarthritis Pathologic changes that occur in OA affect the whole joint and include degradation of the articular cartilage, variable degrees of synovial inflammation, thickening of the subchondral bone, or, in other words, remodeling, hypertrophy of the joint capsule, and osteophyte formation

High levels of triglycerides can also trigger platelet function and increased fibrinogen may be caused by the combined effect of inflammatory cytokines and insulin on the liver

European Heart Journal - Cardiovascular Pharmacotherapy 10(4):296306 Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A et al (2021) GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential